Wegovy vs. Zepbound: What the FDA Actually Approved Each One For
The two biggest weight-loss drugs share a category but not identical indications. Here's what each label actually says.
I now have everything I need. Let me write the article.
Wegovy vs. Zepbound: What the FDA Actually Approved Each One For
Most people assume these two drugs are interchangeable — same category, same weekly shot, same goal. They're not. The FDA approved Wegovy (semaglutide) and Zepbound (tirzepatide) for overlapping but meaningfully different indications, and those differences matter when you and your prescriber are figuring out which one fits your situation.
Here's what the official labels actually say.
How They Work — and Why That Matters
Wegovy is a GLP-1 receptor agonist. It mimics a gut hormone that signals fullness and slows digestion. According to the FDA's Wegovy label, the active ingredient is semaglutide, made by Novo Nordisk.
Zepbound does something extra. The FDA's Zepbound label describes tirzepatide as a dual GIP and GLP-1 receptor agonist — it activates two different hormone pathways. That dual action is the core reason researchers have been so interested in comparing the two.
Neither drug is a standalone fix. Both labels specify use "in combination with a reduced-calorie diet and increased physical activity." That language isn't a footnote — it's part of the official indication.
Who Wegovy Is FDA-Approved For
The FDA approved Wegovy for a broader set of conditions than most people realize. Per the official label, it's indicated for:
- Adults and adolescents aged 12 and older with obesity (not just adults)
- Adults with overweight who have at least one weight-related condition (like high blood pressure or high cholesterol)
- Adults with established cardiovascular disease and obesity or overweight — specifically to reduce the risk of CV death, non-fatal heart attack, or non-fatal stroke
- Adults with a liver condition called MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH) with moderate to advanced fibrosis — though the label notes this approval is under accelerated approval pending a confirmatory trial
That cardiovascular indication came from the SELECT trial. Lincoff et al. in the New England Journal of Medicine (2023) found semaglutide reduced major adverse cardiovascular events in people with obesity who did not have diabetes — a landmark result that pushed Wegovy beyond just a weight-loss drug.
Who Zepbound Is FDA-Approved For
Zepbound's label is currently narrower in some ways, but it has one approval Wegovy doesn't. Per the FDA label, Zepbound is approved for:
- Adults with obesity, or adults with overweight plus at least one weight-related condition — long-term weight reduction
- Adults with moderate to severe obstructive sleep apnea (OSA) and obesity — this is a distinct, separate indication Wegovy does not currently carry
The sleep apnea indication came from the SURMOUNT-OSA trial. Malhotra et al. in the New England Journal of Medicine (2024) studied tirzepatide specifically in OSA patients with obesity — and that trial data is what drove the FDA approval. If you have obesity and OSA, that's a clinically relevant difference on paper.
Note that Zepbound's current label covers adults only — it does not include an adolescent indication the way Wegovy does.
How They Compare Head-to-Head in Research
The labels tell you what's approved. Published research tells you what's been observed in real-world use.
A 2024 study in JAMA Internal Medicine by Rodriguez et al. compared semaglutide and tirzepatide for weight loss in adults with overweight or obesity and found tirzepatide was associated with greater weight reduction — though the authors note this was a real-world observational study, not a randomized controlled trial, so direct comparison has limits.
A 2024 systematic review and network meta-analysis in Diabetologia by Karagiannis et al. looked at tirzepatide vs. semaglutide specifically in type 2 diabetes and found tirzepatide showed greater HbA1c and weight reductions across doses studied.
Neither of these studies tells you which drug you should take. That depends on your full medical history, not a population average.
Shared Warnings You Should Know
Both labels carry the same serious warning categories, according to the FDA. These include:
- Risk of thyroid C-cell tumors (seen in animal studies; both labels carry a boxed warning)
- Acute pancreatitis — both labels say to discontinue if suspected
- Acute gallbladder disease
- Severe gastrointestinal reactions — nausea, vomiting, diarrhea are the most commonly reported adverse events (reported in ≥5% of patients on both drugs)
- Neither is recommended for people with severe gastroparesis
- Both carry a warning against use with other GLP-1 receptor agonists simultaneously
The adverse reactions listed on both labels are reported events from clinical trials, not confirmed causal relationships — that's standard FDA framing, and it's worth keeping in mind.
What This Means for You
- Wegovy has more approved indications right now — including cardiovascular risk reduction, adolescent use (12+), and MASH liver disease. If any of those apply to you, it may be the more relevant conversation to have with your prescriber.
- Zepbound is the only one with an FDA-approved sleep apnea indication. If you have obesity plus diagnosed moderate-to-severe OSA, that's worth raising with your doctor specifically.
- Neither drug is approved for people without obesity or a weight-related condition. Both labels require at least one comorbidity if you fall in the "overweight" (not obese) category — the FDA's definition of obesity starts at a BMI of 30, per MedlinePlus.
Not medical advice. Talk to your prescriber about your specific health history, current conditions, and which option — if any — is right for you.
